BRIEF-Cormedix Announces FDA Acceptance For Priority Review Of Supplemental NDA For Rezzayo

1

Oct 19 (Reuters) – CorMedix Inc.: * ANNOUNCES FDA ACCEPTANCE FOR PRIORITY REVIEW OF SUPPLEMENTAL NDA FOR REZZAYO® (REZAFUNGIN) FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASES * FDA GRANTS PRIORITY REVIEW

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)